When was Connect founded?

Connect was founded in 2015 and raised its 1st funding round 11 years after it was founded.

Where is Connect located?

Connect is headquartered in San Diego, United States.

Is Connect a funded company?

Connect is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Mar 30, 2026.

When was the latest funding round of Connect?

Connect's latest funding was a $***** Post IPO round on Mar 30, 2026, with participation from 0 investor.

Where does Connect rank among its competitors?

Connect ranks 393rd amongst 416 active competitors, of which 140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Connect, which secured $20.2M in Mar, 2026.

Who are the top competitors of Connect?

Connect's top competitors include BeiGene, Biogen and argenx. Among them, Connect secured the most recent funding round in March, 2026.

Connect - 2026 Company Profile, Funding & Competitors

Connect is a late stage company based in San Diego (United States), founded in 2015. It operates as a Developer of drugs for the treatment of autoimmune and inflammatory diseases. Connect has raised an undisclosed amount in funding from PanaceaCapital. The company has 416 active competitors, including 140 funded and 115 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.

Company Details

Developer of drugs for the treatment of autoimmune and inflammatory diseases. The company focuses on developing innovative therapies for chronic inflammatory diseases, particularly asthma, COPD, and atopic dermatitis, using T cell-driven research to create small molecules and antibodies.

Website: www.connectbiopharma.com/
Email ID: *****@connectpharm.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

San Diego, United States

Stage

Late Stage

Latest Funding Round

Post IPO, Mar 30, 2026, $*****

Investors

PanaceaCapital

Ranked

393^rd among 416 active competitors

Similar Companies

BeiGene & 486 more

View Connect's full profile

Connect has raised funding over 1 round. Connect has 1 institutional investor.

Here is the list of recent funding rounds of Connect:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 30, 2026	9678732	Post IPO	8299599	2107980	6306725	4595260

Access funding benchmarks and valuations. Sign up today!

View details of Connect's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Connect include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of Connect, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	General Atlantic, BlackRock & 50 others	69/100
8th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
9th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
393rd	Connect 2015, San Diego (United States), Late Stage	Developer of drugs for the treatment of autoimmune and inflammatory diseases	-	-	22/100